Global Retirement Partners LLC Trims Position in Sanofi (NASDAQ:SNY)

Global Retirement Partners LLC trimmed its position in Sanofi (NASDAQ:SNY) by 4.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,028 shares of the company’s stock after selling 287 shares during the period. Global Retirement Partners LLC’s holdings in Sanofi were worth $291,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Synergy Asset Management LLC bought a new stake in Sanofi during the fourth quarter valued at $25,000. McClarren Financial Advisors Inc. boosted its position in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Concord Wealth Partners boosted its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Fortitude Family Office LLC grew its holdings in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its position in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Down 1.3 %

Shares of SNY opened at $53.75 on Tuesday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a 50 day simple moving average of $51.10 and a two-hundred day simple moving average of $52.55. The firm has a market cap of $136.41 billion, a P/E ratio of 21.59, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.